<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03060447</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-382-3961</org_study_id>
    <nct_id>NCT03060447</nct_id>
  </id_info>
  <brief_title>Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated HIV-1 Infected Controllers</brief_title>
  <official_title>A Phase 1b, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of GS-9620 in Antiretroviral Treated HIV-1 Infected Controllers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and tolerability of a 10-dose
      regimen of vesatolimod in HIV-1 infected controllers on antiretroviral treatment (ART) and
      during analytical treatment interruption (ATI) following vesatolimod dosing.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 9, 2017</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Safety Profile as Assessed by Percentage of Participants Experiencing Treatment-Emergent Serious Adverse Events (SAEs) and all Treatment-Emergent Adverse Events.</measure>
    <time_frame>Up to 45 weeks plus 30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Virology: Changes in Plasma HIV-1 RNA and Cell Associated Viral RNA (CAVR) During the Dosing Period</measure>
    <time_frame>Up to 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virology: Changes in Peripheral Blood Mononuclear Cell (PBMC) HIV-1 Reservoir Between Baseline and Following Vesatolimod Dosing</measure>
    <time_frame>Up to 45 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virology: Changes in Total CD4+ T Cell Reservoirs</measure>
    <time_frame>Up to 45 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virology: Time to Virologic Rebound and Plasma Viral Load Set-Point Following ATI</measure>
    <time_frame>Up to 25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virology: Peak HIV-1 Viral Load During Period 2</measure>
    <time_frame>Up to 25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunology/Pharmacodynamics: Changes in Serum/Plasma Cytokines</measure>
    <time_frame>Up to 45 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunology/Pharmacodynamics: Changes in Plasma Kynurenine/ Tryptophan (K/T)</measure>
    <time_frame>Up to 45 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunology/Pharmacodynamics: Changes in mRNA of Interferon-Stimulated Genes (ISGs) in Whole Blood</measure>
    <time_frame>Up to 45 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunology/Pharmacodynamics: Changes in Immune cell Activation</measure>
    <time_frame>Up to 45 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunology/Pharmacodynamics: Changes in HIV-1 Specific T cell Immune Responses</measure>
    <time_frame>Up to 45 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunology/Pharmacodynamics: Changes in the Frequency of Regulatory T cells</measure>
    <time_frame>Up to 45 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunology/Pharmacodynamics: Changes in the Quantity of HIV-Specific Antibodies</measure>
    <time_frame>Up to 45 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunology/Pharmacodynamics: Changes in the Quality (Effector Functionality) of HIV-Specific Antibodies</measure>
    <time_frame>Up to 45 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunology/Pharmacodynamics: Change in Plasma Inflammatory Markers</measure>
    <time_frame>Up to 45 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Parameter: Cmax of Vesatolimod</measure>
    <time_frame>Up to 45 weeks</time_frame>
    <description>Cmax is defined as maximum observed concentration of drug in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Ctau of Vesatolimod</measure>
    <time_frame>Up to 45 weeks</time_frame>
    <description>Ctau is defined as the observed drug concentration at the end of the dosing interval (tau)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: AUCtau of Vesatolimod</measure>
    <time_frame>Up to 45 weeks</time_frame>
    <description>AUCtau is defined as the area under the plasma concentration versus time curve over the dosing interval (tau)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Vesatolimod</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Participants will receive up to 10 doses of vesatolimod. Participants will continue to take their prescribed ART during this period.
Period 2: All participants will discontinue ART and be monitored for rebound in HIV-1 plasma viremia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vesatolimod placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Participants will receive up to 10 doses of vesatolimod placebo. Participants will continue to take their prescribed ART during this period.
Period 2: All participants will discontinue ART and be monitored for rebound in HIV-1 plasma viremia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vesatolimod</intervention_name>
    <description>6 mg dose administered as three 2 mg tablets orally every 14 days</description>
    <arm_group_label>Vesatolimod</arm_group_label>
    <other_name>GS-9620</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vesatolimod Placebo</intervention_name>
    <description>Tablet administered orally once every 14 days</description>
    <arm_group_label>Vesatolimod placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ART</intervention_name>
    <description>ART regimens administered in accordance with their Prescribing Information</description>
    <arm_group_label>Vesatolimod</arm_group_label>
    <arm_group_label>Vesatolimod placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Plasma HIV-1 RNA levels &lt;50 copies/mL at screening

          -  Chronic HIV-1 infection (for ≥ 6 months) prior to ART initiation

          -  Pre-ART Plasma HIV-1 RNA set point between 50 and ≤ 5,000 copies/mL measured within
             two years prior to ART initiation

          -  On ART for ≥ 6 months prior to screening

          -  Documented plasma HIV-1 RNA &lt; 50 copies/mL for ≥ 6 months preceding the screening
             visit (or undetectable HIV-1 RNA level according to the local assay being used if the
             limit of detection is ≥ 50 copies/mL). Unconfirmed virologic elevations of ≥ 50
             copies/mL (transient detectable viremia, or &quot;blip&quot;) prior to screening are acceptable.

          -  No documented history of resistance to any components of the current ART regimen

          -  Availability of a fully active alternative ART regimen, in the opinion of the
             Investigator, in the event of discontinuation of the current ART regimen with
             development of resistance.

          -  Hemoglobin ≥ 11.5 g/dL (males) or ≥ 11 g/dL (females)

          -  White Blood Cells ≥ 2,500 cells/μL

          -  Platelets ≥ 125,000/mL

          -  Absolute Neutrophil Counts ≥ 1000 cells/μL

          -  CD4+ count ≥ 500 cells/μL

          -  Alanine aminotransferase (ALT), aspartate aminotransferase (AST) or bilirubin ≤ 2 ×
             upper limit of normal (ULN)

          -  Estimated glomerular filtration rate ≥ 60 mL/min

          -  No autoimmune disease requiring on-going immunosuppression

          -  No evidence of current hepatitis B virus (HBV) infection

          -  No evidence of current hepatitis C virus (HCV) infection (positive anti-HCV antibody
             and negative HCV polymerase chain reaction (PCR) results are acceptable)

          -  No documented history of pre-ART CD4 nadir &lt; 200 cells/μL (unknown pre-ART CD4 nadir
             is acceptable)

          -  No history of opportunistic illness indicative of stage 3 HIV

          -  No acute febrile illness within 35 days prior to Pre-Baseline/ Day -13

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilead Clinical Study Information Center</last_name>
    <phone>1-833-445-3230 (GILEAD-0)</phone>
    <email>GileadClinicalTrials@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mills Clinical Research</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zuckerberg San Francisco General</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Midway Immunology &amp; Research Center</name>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <zip>34982</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Central Texas Clinical Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peter Shalit, MD</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2017</study_first_submitted>
  <study_first_submitted_qc>February 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

